Phase 2 Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with dilated cardiomyopathy (a condition where the heart is enlarged and weakened) whose heart is still not pumping well enough, even with treatment, as confirmed by specific heart scan measurements
- People whose heart condition is classified as moderately symptomatic (known as NYHA Class II or III, meaning symptoms appear during normal or mild activity)
- People who have normal or high levels of cholesterol or triglycerides (fats in the blood)
- People who have been on heart failure medications for at least three months and whose heart function has remained poor
- People whose heart failure symptoms have stayed the same or gotten worse after one month of heart failure medications
- People with a family history of dilated cardiomyopathy who have been on heart failure medications for at least one month
- People (or their parents or guardians) who are able and willing to sign a consent form agreeing to take part
Who may not be able to join:
- People who have had heart surgery in the past, unless the surgery was related to dilated cardiomyopathy (such as mitral valve repair) and took place more than one year ago
- People with active liver or kidney problems
- People currently taking certain medications that interact with the study drug, including gemfibrozil, cyclosporine, danazol, certain HIV medicines, or specific antifungal or antibiotic medications (confirm with trial site for the full list)
- People who are pregnant or planning to become pregnant during the study period
- People who are unable to tolerate the medication simvastatin
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Wei-Chieh Tseng, MD, Principal Investigator
Phone: 0972652584
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Improvement in left ventricular ejection fraction and NT-pro BNP (biomarker for left ventricular function))
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.